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Background
Systemic inflammation or activation of renin-angiotensin-
aldosterone system (RAAS) play the essential role in the
development of lifestyle-related disease. There is mounting
evidence suggesting that systemic inflammation influences
cancer growth, invasion, and metastasis. Furthermore,
recent study has shown that activation of RAAS enhanced
cancer metastasis.
Atrial natriuretic peptide (ANP) has been used clinically
for the treatment with heart failure in Japan, and exhibits
a wide range of cardioprotective effects, including antifi-
brosis, antihypertrophy, antiinflammation, and inhibition
of RAAS through binding the guanylate cyclase-A (GC-A)
receptor. This study was designed to examine whether
ANP pretreatment attenuates pulmonary metastasis
enhanced by lipopolysaccharide (LPS) or angiotensin-II.
Materials and methods
We used B16 mice melanoma cell line, which don’t have
the GC-A receptor and angiotensin-II receptor, in the
experimental hematogenous metastasis model in mice.
We administered intravenously a dose of 1mg/kg LPS
4 hours before the injection of B16 cells, or angiotensin-II
(subcutaneously via osmotic pump, 1mg/kg/min) 3 days
before the injection of B16 cells.
ANP infusion (subcutaneously via osmotic-pump,
0.5 μg/kg/min) was started one day before the injection
of B16 cells. This dose does not change blood pressure
and heart rate in mice.
Results
Mice with LPS or angiotensin-II showed increasing of
pulmonary metastasis compared to the control mice.
The number of pulmonary metastasis of B16 melanoma
(2.0 × 105 cell/body) in 2 weeks was significantly lower
ANP-pretreated mice compared to the control mice
with LPS (62 ± 12 vs. 248 ± 36, P < 0.001). Mice with angio-
tensin-II receptor blocker (Candesartan; oral, 8mg/kg/day)
inhibited pulmonary metastasis of B16 melanoma enhanced
by angiotensin-II. In addition, ANP-pretreated mice also
showed the reduction of the number of pulmonary metas-
tasis compared to the control mice with angiotensin-II.
Conclusion
We found that ANP inhibited the induction of pulmon-
ary metastasis by LPS or angiotensin-II. Our data pro-
vide novel insights into the prophylactic therapy in the
cancer patients with lifestyle-related disease or during
the perioperative period.
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